UCB-0022
- Generic Name
- UCB-0022
A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 32
- Registration Number
- NCT06970301
- Locations
- 🇺🇸
Up0135 1001, Glendale, California, United States
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 207
- Registration Number
- NCT06055985
- Locations
- 🇺🇸
Pd0060 50580, Miami, Florida, United States
🇺🇸Pd0060 50597, Naples, Florida, United States
🇺🇸Pd0060 50591, Ocala, Florida, United States
A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease
Phase 1
Completed
- Conditions
- Healthy Study ParticipantsParkinson's Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 100
- Registration Number
- NCT04867642
- Locations
- 🇬🇧
Up0091 001, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath